Effect of rifampicin on the pharmacokinetics of atenolol

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 6, 2006, Pages 555-558

  Lilja, Jari J ^a   Juntti Patinen, Laura ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATENBLOCK; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; HEART RATE; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VOLUNTEER;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; RIFAMPIN;

EID: 33646749945     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_379.x     Document Type: Article

References (22)

1. Augustijns P. R. Mols : HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. J. Pharm. Biomed. Anal. 2004, 34, 971 978.
2. Cabrera K. D. Lubda H.-M. Eggenweiler H. Minakuchi K. Nakanishi : R&D biochemistry and separation, Merck KgaA: a new monolithic-type HPLC column for fast separations. J. High Resolut. Chromatogr. 2000, 23, 93 99.
3. Dollery C. Ed. : Therapeutic drugs, vol 1. Churchill Livingstone, Edinburgh, Great Britain, 1999, pp. A224 A227.
4. Doppenschmitt S. H. Spahn-Langguth C. G. Regårdh P. Langguth : Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 1999, 88, 1067 1072.
5. Findlay I. N. G. T. McInness H. J. Dargie : β blockers and verapamil: a cautionary tale. Brit. Med. J. 1984, 289, 1074.
6. Fromm M. F. H.-M. Kauffmann P. Friz O. Burk H. K. Kroemer R. W. Warzok W. Siegmund D. Schrenk : The effect of rifampin on intestinal expression of human MRP transporters. Amer. J. Pathol. 2000, 157, 1575 1580.
7. Goldberg S. V. D. Hanson C. A. Peloquin : Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin. Clin. Infect. Dis. 2003, 37, 607 608.
8. Gottesman M. M. G. H. Mickisch I. Pastan : In vivo models of P-glycoprotein mediated multidrug resistance. Cancer Treat. Res. 1994, 73, 107 128.
9. Greiner B. M. Eichelbaum P. Fritz H. P. Kreichgauer O. von Richter J. Zundler H. K. Kroemer : The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104, 147 153.
10. Hamman M. A. M. A. Bruce B. D. Haehner-Daniels S. D. Hall : The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Therap. 2001, 69, 114 121.
11. Keech A. C. R. W. Harper P. M. Harrison A. Pitt A. J. McLean : Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man. Eur. J. Clin. Pharmacol. 1988, 35, 363 366.
12. Klein H. O. R. Lang E. Weiss E. Di Segni C. Libhaber J. Guerrero E. Kaplinsky : The influence of verapamil on serum digoxin concentration. Circulation 1982, 65, 998 1003.
13. Kyrklund C. J. T. Backman M. Neuvonen P. J. Neuvonen : Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Brit. J. Clin. Pharmacol. 2004, 57, 181 187.
14. Läer S. I. Wauer H. Scholz : Small blood volumes from children for quantitative sotalol determination using high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 2001, 753, 421 425.
15. Lilja J. J. J. T. Backman J. Laitila H. Luurila P. J. Neuvonen : Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Therap. 2003, 73, 192 198.
16. Lilja J. J. M. Niemi P. J. Neuvonen : Rifampicin reduces plasma concentrations of celiprolol. Eur. J. Clin. Pharmacol. 2004, 59, 819 824.
17. Misra M. R. Thakur K. Bhandari : Sinus arrest caused by atenolol-verapamil combination. Clin. Cardiol. 1987, 10, 365 367.
18. Niemi M. J. T. Backman M. F. Fromm P. J. Neuvonen K. Kivistö : Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 2003, 42, 819 850.
19. Partanen J. K.-M. Jalava P. J. Neuvonen : Itraconazole increases serum digoxin concentrations. Pharmacology & Toxicology 1996, 79, 274 276.
20. Sagie A. B. Strasberg J. Kusnieck S. Sclarovsky : Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin. Cardiol. 1991, 14, 314 316.
21. Wan S. H. R. T. Koda R. F. Maronde : Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Brit. J. Clin. Pharmacol. 1979, 7, 569 574.
22. Westphal K. A. Weinbrenner M. Zschiesche G. Franke M. Knoke R. Oertel P. Fritz O. von Richter R. Warzok B. Hachenberg, H.-M. Kauffmann D. Schrenk B. Terhaag H. K. Kroemer W. Siegmund : Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Therap. 2000, 68, 345 355.